Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/31/2024 | $18.00 | Buy | H.C. Wainwright |
| 7/11/2024 | $11.00 | Overweight | Cantor Fitzgerald |
| 2/25/2022 | $24.00 → $12.00 | Buy → Hold | Jefferies |
WASHINGTON, April 7, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced participation at the American Academy of Neurology (AAN) Annual Meeting, to be held in San Diego, California from April 5 through April 9, 2025. The following will be presented: April 9, 2025 Presentation Title: "Translating IGHMBP2 Variants with a CMT2S Patient-specific Organ-on-a-chip Model: Personalized Medicine ASO-based Therapeutic Rescue" Poster Presentation Session: P-12 Poster Number: 11-017 Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics This poster de
WASHINGTON, March 31, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) requesting marketing approval of Bysanti™ (milsaperidone) for the treatments of acute bipolar I disorder and schizophrenia. The NDA is supported by several clinical studies assessing the efficacy and safety of Bysanti™. Bysanti™ is a new chemical entity that belongs in the class of atypical antipsychotic drugs. Bysanti™ is believed to achieve its therapeutic effect by interacti
WASHINGTON, Feb. 24, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the publication of an article entitled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S" in Molecular Therapy Nucleic Acids1, a Cell Press partner journal, that describes the development of a novel antisense oligonucleotide (ASO) therapeutic, VCA-894A, for a patient with a rare variant in the IGHMBP2 gene causing Charcot-Marie-Tooth disease Type 2S (CMT2S). In 1886, Jean-Martin Charcot, Pierre Marie, and Henry Tooth independently describ
Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling
Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling
Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
H.C. Wainwright initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $18.00
Cantor Fitzgerald initiated coverage of Vanda Pharma with a rating of Overweight and set a new price target of $11.00
Jefferies downgraded Vanda Pharmaceuticals from Buy to Hold and set a new price target of $12.00 from $24.00 previously
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)
Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023Q4 2024 Fanapt® net product sales of $26.6 million, +18% compared to Q4 2023Full year 2024 total revenues of $198.8 million, +3% compared to full year 2023Full year 2025 revenue expected to grow to $210 to $250 millionPsychiatry portfolio revenue expected to grow to greater than $750 million in 2030Fanapt® MAA for bipolar I disorder and schizophrenia submitted in Q4 2024BysantiTM (milsaperidone) NDA for bipolar I disorder and schizophrenia expected to be submitted in Q1 2025HETLIOZ® MAA for Smith-Magenis syndrome submitted in Q4 2024Tradipitant NDA for motion sickness submitted in Q4 2024Imsidolimab BLA in generalized pustular
Conference Call and Webcast to Follow WASHINGTON, Feb. 5, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the fourth quarter and full year 2024 on Thursday, February 13, 2025, after the market closes. Vanda will host a conference call at 4:30 PM ET on Thursday, February 13, 2025, during which management will discuss the fourth quarter and full year 2024 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international
Revenues for Q3 2024 were $47.7 million, an increase of 23% compared to Q3 2023Financial Guidance revised for Full Year 2024, raising the midpoint of revenue and cash rangesFanapt® launch in bipolar I disorder; new patient starts increased by over 90% in Q3 2024 as compared to Q3 2023Fanapt® long acting injectable program expected to be initiated in Q4 2024Milsaperidone NDA for schizophrenia and bipolar I disorder expected to be submitted in early 2025; initiation of major depressive disorder program expected in Q4 2024PONVORY® commercial launch for multiple sclerosis initiated in Q3 2024PONVORY® IND applications for psoriasis and ulcerative colitis expected to be submitted in Q4 2024Tradipi
WASHINGTON, March 17, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the appointment of Tage Honoré, Ph.D., D.Sc. to its Board of Directors effective March 15, 2023. Following Dr. Honoré's appointment, Vanda's Board of Directors is now comprised of six directors, five of whom are independent. "Tage is a highly accomplished industry leader and respected scientist with deep experience across a diverse range of therapeutic areas," said Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board. "We are confident that his scientific expertise and executive experience will be invaluable, and look forward to working with him as we contin
SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
SC 13G/A - Vanda Pharmaceuticals Inc. (0001347178) (Subject)
8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)
8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)
10-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)